Last Updated: November 16, 2026

Investigational Drug Information for Hetrombopag

« Back to Dashboard


What is the drug development status for Hetrombopag?

Hetrombopag is an investigational drug.

There have been 43 clinical trials for Hetrombopag. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2024.

The most common disease conditions in clinical trials are Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic, and Anemia, Aplastic. The leading clinical trial sponsors are Jiangsu HengRui Medicine Co., Ltd., Peking Union Medical College Hospital, and Henan Cancer Hospital.

There are eleven US patents protecting this investigational drug and fifty-one international patents.

Recent Clinical Trials for Hetrombopag
TitleSponsorPhase
A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced ThrombocytopeniaJiangsu HengRui Medicine Co., Ltd.PHASE3
A Study of Hetrombopag Combined With rhTPO in the Treatment of Cancer Therapy-induced Thrombocytopenia (CTIT) in Solid Tumor Patients.Sun Yat-sen UniversityPHASE2
Hetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 StudyFujian Cancer HospitalPHASE2

See all Hetrombopag clinical trials

Clinical Trial Summary for Hetrombopag

Top disease conditions for Hetrombopag
Top clinical trial sponsors for Hetrombopag

See all Hetrombopag clinical trials

US Patents for Hetrombopag

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Hetrombopag ⤷  Start Trial Controlled release dosage form TRIASTEK, INC. (Nanjing, CN) ⤷  Start Trial
Hetrombopag ⤷  Start Trial Pharmaceutical composition comprising bicyclo-substituted pyrazolon azo derivative or salt thereof and preparation method thereof Jiangsu Hengrui Medicine Co Ltd ⤷  Start Trial
Hetrombopag ⤷  Start Trial Oral drug dosage form comprising various release profiles Triastek Inc ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

Hetrombopag Development Update and Market Projection

Last updated: September 6, 2026

Hetrombopag is a China-approved oral thrombopoietin receptor agonist developed by Jiangsu Hengrui Pharmaceuticals. Its commercial indications are chronic immune thrombocytopenia (ITP) and severe aplastic anemia (SAA). The drug is marketed in China as hetrombopag olamine tablets, with the brand commonly identified as Hengqu. It is not approved by the U.S. FDA or European Medicines Agency as of June 2024.

The near-term opportunity is concentrated in China. Hetrombopag competes with eltrombopag and avatrombopag in ITP and SAA, but its international value remains limited until Hengrui establishes licensing, regulatory, and clinical-development partnerships outside China. A reasonable base-case projection is China sales of approximately RMB 500 million to RMB 900 million by 2028, subject to reimbursement access, hospital adoption, and pricing pressure.

What is hetrombopag and how does it work?

Hetrombopag olamine is an orally administered, nonpeptide thrombopoietin receptor agonist. It stimulates the thrombopoietin receptor, also known as MPL, on megakaryocyte-lineage cells and increases platelet production.

The product is pharmacologically related to eltrombopag but is a separate chemical entity. It is not a biosimilar and does not rely on an injectable biologic manufacturing platform.

Attribute Hetrombopag
Active ingredient Hetrombopag olamine
Drug class Oral thrombopoietin receptor agonist
Primary developer Jiangsu Hengrui Pharmaceuticals
Dosage form Oral tablets
Main commercial market China
Initial approved indication Adult chronic ITP after inadequate response to prior therapy
Additional indication Severe aplastic anemia
U.S. approval None identified as of June 2024
European approval None identified as of June 2024
Main competitors Eltrombopag, avatrombopag, romiplostim

Hetrombopag has a differentiated chemical structure from eltrombopag. The commercial rationale is to provide a domestic oral TPO-receptor agonist with potentially lower pricing than imported products and expanded access through China’s hospital and reimbursement systems.

What is the regulatory status of hetrombopag?

China’s National Medical Products Administration approved hetrombopag olamine tablets for adult patients with chronic ITP who had an inadequate response to other treatments in 2021. Hengrui subsequently obtained approval for use in SAA, expanding the addressable population beyond ITP. The approvals were based on Chinese clinical development programs evaluating platelet response and hematologic recovery.

The product does not have an identified FDA approval, biologics license application, or publicly established U.S. commercial launch. No European marketing authorization is identified in the public regulatory record through June 2024.

Regulatory status by market

Market Status Commercial implication
China Approved for ITP and SAA Active commercial market
United States Not approved No U.S. product revenue
European Union Not approved No EU product revenue
Japan No major approval identified Limited direct access
Other Asia-Pacific markets No broad approval footprint identified Partnership-dependent opportunity

The absence of U.S. and European approval sharply limits global revenue potential. International expansion would require additional clinical data, chemistry and manufacturing documentation, pharmacovigilance infrastructure, and country-specific reimbursement strategies.

What clinical development supports hetrombopag?

Hetrombopag’s clinical development has focused on platelet elevation in ITP and hematologic improvement in SAA.

In ITP, the development objective is durable platelet response sufficient to reduce bleeding risk and the need for rescue therapy. The relevant competitive benchmark is eltrombopag, which has an established treatment position in chronic ITP.

In SAA, the development opportunity is more specialized. Patients may require immunosuppressive therapy, hematopoietic stem-cell transplantation, or thrombopoietin-receptor agonist treatment. Eltrombopag has established evidence in SAA, making efficacy, tolerability, treatment sequencing, and price central to hetrombopag adoption.

Development strengths

  • Oral administration
  • Two approved hematology indications in China
  • Domestic manufacturing and distribution infrastructure
  • Potentially lower price than imported TPO-receptor agonists
  • Use in diseases with chronic treatment requirements

Development limitations

  • No established U.S. or EU development program
  • Limited publicly visible global phase 3 activity
  • Small patient populations relative to common hematology indications
  • Competition from drugs with longer safety and efficacy histories
  • Need for long-term data on thrombosis, marrow fibrosis, hepatotoxicity, and clonal evolution in SAA

How does hetrombopag compare with eltrombopag and avatrombopag?

Hetrombopag competes most directly with eltrombopag because both are oral small-molecule TPO-receptor agonists used in ITP and SAA. Avatrombopag is a more recent oral competitor with use in ITP and thrombocytopenia associated with chronic liver disease and procedures, depending on jurisdiction.

Factor Hetrombopag Eltrombopag Avatrombopag
Administration Oral Oral Oral
China approval ITP and SAA Broad hematology use Approved in selected indications
Global approval Limited Extensive Extensive but narrower
SAA positioning Commercially relevant in China Established global position Less central
Food and mineral restrictions Product-specific Important calcium and polyvalent-cation restrictions Generally less restrictive
China pricing position Potentially competitive Imported and locally commercialized Competitive pressure varies
Clinical evidence depth Lower globally High High in approved indications
International access Limited Broad Broad

Eltrombopag retains the evidence advantage. Hetrombopag’s strongest competitive argument is price and domestic availability rather than superior global clinical differentiation.

What is the market size for hetrombopag?

The primary market is China’s treated ITP and SAA population.

ITP is a chronic autoimmune platelet disorder. The commercially relevant population is smaller than total prevalence because not all patients require long-term TPO-receptor agonist treatment. Treatment persistence, line of therapy, reimbursement rules, and physician preference determine the usable market.

SAA is a smaller population but has higher treatment intensity. Drug demand can be concentrated among specialist hematology centers, particularly when patients are not transplant candidates, have relapsed disease, or require an alternative to conventional immunosuppression.

China market projection

The following projection is a scenario model rather than company guidance. It assumes continued reimbursement access, gradual hospital penetration, and price competition with eltrombopag.

Year Estimated China net sales Main assumptions
2023 RMB 150 million-300 million Early post-launch adoption
2024 RMB 220 million-400 million Wider hospital listing and physician use
2025 RMB 300 million-550 million Greater ITP penetration and SAA uptake
2026 RMB 380 million-700 million Reimbursement scale and repeat treatment
2027 RMB 450 million-800 million Mature specialist adoption
2028 RMB 500 million-900 million Established domestic niche product

A base case of approximately RMB 700 million in 2028 implies a compound annual growth rate of roughly 20% to 25% from a modeled 2024 base of RMB 275 million. The high case requires greater substitution from eltrombopag and strong SAA uptake. The low case reflects centralized purchasing, lower reimbursement prices, and increased competition from avatrombopag and other domestic TPO-receptor agonists.

Revenue sensitivity

Variable Downside effect Upside effect
Reimbursement price Lower net sales despite volume growth Improved access and faster volume expansion
Hospital inclusion Slower physician adoption Broader prescribing
ITP persistence Lower annual treatment revenue More recurring revenue
SAA positioning Limited use after failed therapy Higher-value specialist use
Generic or local competition Price erosion Limited if product differentiation persists
Overseas licensing No additional revenue Milestone and royalty upside

No reliable public evidence establishes a material revenue contribution from the United States or Europe. Any global projection should therefore assign international sales a low probability until Hengrui discloses regulatory filings or a regional licensing transaction.

What patents protect hetrombopag?

Hetrombopag is protected through a combination of compound, salt, formulation, process, and therapeutic-use rights. Public product information does not establish one universally applicable global patent-expiration date for all commercial claims.

The relevant patent categories are:

  1. Composition-of-matter patents covering the hetrombopag chemical structure.
  2. Salt and polymorph patents covering hetrombopag olamine and solid-state forms.
  3. Pharmaceutical-composition patents covering tablet formulations and excipients.
  4. Manufacturing patents covering synthesis, purification, crystallization, and scale-up.
  5. Method-of-use patents covering treatment of ITP, SAA, or platelet disorders.
  6. Regional patents that may have different filing dates, prosecution outcomes, and term adjustments.

The commercial strength of the estate depends on claim scope and the jurisdictions in which patents remain enforceable. A compound patent generally provides the strongest protection. Formulation and process patents may extend practical barriers but are more vulnerable to design-around strategies.

Orange Book status and generic entry

Hetrombopag has no identified U.S. FDA approval and therefore has no U.S. Orange Book listing associated with an approved product. U.S. Paragraph IV litigation is not a meaningful current commercial issue because a listed reference product and U.S. ANDA pathway have not been established.

In China, generic or competing-product risk is more relevant. Competitors could challenge compound, formulation, or use claims, or pursue regulatory development based on non-infringing processes and alternative dosage forms. The timing of entry will depend on Chinese patent expiration, invalidation proceedings, regulatory filing rules, and market access decisions.

What patent litigation and settlement agreements affect hetrombopag?

No major publicly reported U.S. patent litigation or Paragraph IV settlement involving hetrombopag was identified through June 2024. No material global settlement agreement has been publicly disclosed that would determine generic entry timing.

The principal legal risks are likely to arise in China from:

  • Invalidity challenges to compound or salt claims
  • Infringement disputes involving manufacturing routes
  • Competing formulations
  • Method-of-use claims for ITP and SAA
  • Patent linkage or premarketing disputes involving follow-on products

The absence of disclosed litigation should not be interpreted as proof of a broad or weak patent estate. It indicates that the product’s commercial exposure remains centered on China and that public litigation records provide limited visibility.

How strong is the commercial and patent estate?

Hetrombopag has a moderate China commercial position and a weak-to-moderate global position.

Its commercial strengths are regulatory approval in two hematology indications, domestic production, and the ability to compete on price. Its principal weaknesses are limited geographic coverage, lower international clinical visibility, and established competition from eltrombopag.

Its patent strength cannot be rated as high without claim-level review of the Chinese and foreign families. The key distinction is between a surviving broad compound patent and narrower follow-on rights. Broad composition claims would support stronger exclusivity. Formulation and process claims alone would provide less protection against a technically capable competitor.

What generic launch risks exist?

The most likely launch scenario is continued domestic competition after patent or regulatory barriers weaken. Because hetrombopag is a small molecule, it does not face biosimilar competition. It faces conventional generic-drug and branded-generic risks.

Likely entry scenarios

  • A competing oral TPO-receptor agonist captures price-sensitive hospital demand.
  • A generic manufacturer challenges formulation or process claims.
  • A domestic competitor uses an alternative synthesis route.
  • Centralized procurement reduces the net price before patent expiry.
  • Eltrombopag and avatrombopag retain specialist preference because of longer clinical histories.
  • Hengrui protects share through reimbursement access, supply reliability, and lower pricing.

Manufacturing barriers are meaningful but not prohibitive. The active ingredient requires controlled chemical synthesis, impurity management, solid-state control, and validated tablet production. These requirements raise development and quality costs but do not create the biological manufacturing barriers associated with monoclonal antibodies.

What licensing deals could expand hetrombopag’s market?

No major publicly disclosed global licensing transaction was identified through June 2024. A licensing deal would be strategically important because Hengrui lacks a visible commercial footprint comparable to Novartis for eltrombopag or Sobi for avatrombopag.

The most logical targets would be:

  • Southeast Asian markets with growing hematology capacity
  • Latin American markets where lower-cost oral TPO-receptor agonists have value
  • Middle Eastern markets with centralized procurement
  • Selected European or U.S. development partnerships if additional clinical data support registration

A partner would likely require regional rights, regulatory control, manufacturing data, and a clear patent position. Without a partner, international expansion would require substantial investment in pivotal trials and commercial infrastructure.

Key Takeaways

  • Hetrombopag is a China-approved oral TPO-receptor agonist developed by Jiangsu Hengrui.
  • Its approved uses are chronic ITP and SAA.
  • China is the only established commercial market as of June 2024.
  • The drug competes primarily with eltrombopag and avatrombopag.
  • A base-case China sales projection is approximately RMB 500 million to RMB 900 million by 2028.
  • No U.S. FDA approval, Orange Book listing, Paragraph IV case, or major global settlement has been identified.
  • Patent value depends on the surviving scope of compound, salt, formulation, process, and method-of-use claims.
  • The drug is not exposed to biosimilar competition because it is a small molecule.
  • International value depends on licensing or a new regulatory-development program.
  • Pricing, reimbursement, hospital penetration, and domestic competition are the main commercial variables.

FAQs

Is hetrombopag approved in the United States?

No. Hetrombopag had no identified FDA approval or U.S. commercial launch as of June 2024.

Is hetrombopag a biosimilar to eltrombopag?

No. Hetrombopag is a separate small-molecule TPO-receptor agonist. It is not a biosimilar and is not structurally identical to eltrombopag.

Which diseases does hetrombopag treat?

Its China-approved indications are chronic immune thrombocytopenia and severe aplastic anemia.

What is the main commercial risk for hetrombopag?

The main risk is price and market-share pressure from eltrombopag, avatrombopag, and domestic Chinese competitors, compounded by reimbursement controls.

Could hetrombopag become a global product?

Yes, but global commercialization would require new regulatory filings, supporting clinical data, regional partners, and a defensible patent position outside China.

References

  1. China National Medical Products Administration. (2021-2022). Drug approval and product information for hetrombopag olamine tablets. Beijing, China: NMPA.

  2. Jiangsu Hengrui Pharmaceuticals Co., Ltd. (2024). 2023 annual report. Lianyungang, China: Jiangsu Hengrui Pharmaceuticals.

  3. U.S. Food and Drug Administration. (2023). Promacta (eltrombopag) prescribing information. Silver Spring, MD: FDA.

  4. U.S. Food and Drug Administration. (2023). Avatrombopag prescribing information. Silver Spring, MD: FDA.

  5. ClinicalTrials.gov. (2024). Clinical studies of hetrombopag in immune thrombocytopenia and severe aplastic anemia. U.S. National Library of Medicine.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.